O	0	1	A
O	2	12	randomized
O	13	18	Phase
O	19	22	III
O	23	28	trial
O	29	31	of
B-intervention	32	43	neoadjuvant
I-intervention	44	55	recombinant
I-intervention	56	61	human
I-intervention	62	72	endostatin
I-intervention	72	73	,
I-intervention	74	83	docetaxel
I-intervention	84	87	and
I-intervention	88	98	epirubicin
O	99	101	as
O	102	107	first
O	107	108	-
O	108	112	line
O	113	120	therapy
O	121	124	for
O	125	133	patients
O	134	138	with
O	139	145	breast
O	146	152	cancer
O	153	154	(
O	154	161	CBCRT01
O	161	162	)
O	162	163	.

O	164	166	To
O	167	174	further
O	175	181	assess
O	182	185	the
O	186	194	efficacy
O	195	198	and
O	199	205	safety
O	206	208	of
O	209	220	recombinant
O	221	226	human
O	227	237	endostatin
O	238	239	(
O	239	241	rh
O	241	242	-
O	242	252	endostatin
O	252	253	)
O	253	254	,
O	255	256	a
O	257	262	Phase
O	263	266	III
O	266	267	,
O	268	279	multicenter
O	279	280	,
O	281	292	prospective
O	292	293	,
O	294	304	randomized
O	304	305	,
O	306	316	controlled
O	317	325	clinical
O	326	331	trial
O	332	335	was
O	336	345	conducted
O	345	346	.

B-eligibility	347	355	Patients
I-eligibility	356	358	to
I-eligibility	359	361	be
I-eligibility	362	369	treated
I-eligibility	370	374	with
I-eligibility	375	386	neoadjuvant
I-eligibility	387	396	docetaxel
I-eligibility	397	400	and
I-eligibility	401	411	epirubicin
I-eligibility	412	413	(
I-eligibility	413	415	DE
I-eligibility	415	416	)
I-eligibility	417	419	or
I-eligibility	420	422	DE
I-eligibility	423	427	plus
I-eligibility	428	430	rh
I-eligibility	430	431	-
I-eligibility	431	441	endostatin
I-eligibility	442	443	(
I-eligibility	443	446	DEE
I-eligibility	446	447	)
O	448	452	were
O	453	461	eligible
O	462	465	for
O	466	470	this
O	471	476	trial
O	476	477	.

O	478	481	The
O	482	489	primary
O	490	498	endpoint
O	499	502	was
B-outcome-Measure	503	511	clinical
I-outcome-Measure	511	512	/
I-outcome-Measure	512	524	pathological
I-outcome-Measure	525	533	response
O	533	534	.

O	535	544	Secondary
O	545	554	endpoints
O	555	563	included
B-outcome-Measure	564	571	adverse
I-outcome-Measure	572	578	events
I-outcome-Measure	579	582	and
I-outcome-Measure	583	590	quality
I-outcome-Measure	591	593	of
I-outcome-Measure	594	598	life
I-outcome-Measure	599	600	(
I-outcome-Measure	600	603	QOL
I-outcome-Measure	603	604	)
O	604	605	.

O	606	613	Finally
O	613	614	,
B-total-participants	615	618	803
O	619	627	patients
O	628	632	were
O	633	641	enrolled
O	642	645	and
O	646	654	randomly
O	655	663	assigned
O	664	666	to
O	667	674	receive
B-control	675	677	DE
O	678	679	(
O	679	680	n
O	681	682	=
B-control-participants	683	686	402
O	686	687	)
O	688	690	or
O	691	694	DEE
O	695	696	(
O	696	697	n
O	698	699	=
B-intervention-participants	700	703	401
O	703	704	)
O	705	712	regimen
O	712	713	.

O	714	719	After
O	720	725	three
O	726	732	cycles
O	733	735	of
O	736	747	neoadjuvant
O	748	755	therapy
O	755	756	,
B-outcome	757	758	"
I-outcome	758	766	complete
I-outcome	767	775	response
I-outcome	775	776	"
O	777	785	achieved
O	786	788	in
B-iv-bin-percent	789	791	14
I-iv-bin-percent	791	792	.
I-iv-bin-percent	792	793	2
I-iv-bin-percent	793	794	%
O	795	797	of
O	798	806	patients
O	807	809	in
O	810	813	DEE
O	814	819	group
O	820	826	versus
B-cv-bin-percent	827	828	6
I-cv-bin-percent	828	829	.
I-cv-bin-percent	829	830	7
I-cv-bin-percent	830	831	%
O	832	834	in
O	835	837	DE
O	838	843	group
O	843	844	,
B-outcome	845	846	"
I-outcome	846	853	partial
I-outcome	854	862	response
I-outcome	862	863	"
O	864	872	achieved
O	873	875	in
B-iv-bin-percent	876	878	76
I-iv-bin-percent	878	879	.
I-iv-bin-percent	879	880	8
I-iv-bin-percent	880	881	%
O	882	888	versus
B-cv-bin-percent	889	891	71
I-cv-bin-percent	891	892	.
I-cv-bin-percent	892	893	1
I-cv-bin-percent	893	894	%
O	894	895	,
O	896	901	while
B-outcome	902	903	"
I-outcome	903	909	stable
I-outcome	910	917	disease
I-outcome	917	918	"
O	919	921	in
B-iv-bin-percent	922	923	6
I-iv-bin-percent	923	924	.
I-iv-bin-percent	924	925	0
I-iv-bin-percent	925	926	%
O	927	933	versus
B-cv-bin-percent	934	936	18
I-cv-bin-percent	936	937	.
I-cv-bin-percent	937	938	9
I-cv-bin-percent	938	939	%
O	939	940	,
B-outcome	941	942	"
I-outcome	942	953	progressive
I-outcome	954	961	disease
I-outcome	961	962	"
O	963	965	in
B-iv-bin-percent	966	967	3
I-iv-bin-percent	967	968	.
I-iv-bin-percent	968	969	0
I-iv-bin-percent	969	970	%
O	971	977	versus
B-cv-bin-percent	978	979	3
I-cv-bin-percent	979	980	.
I-cv-bin-percent	980	981	2
I-cv-bin-percent	981	982	%
O	983	985	of
O	986	994	patients
O	994	995	.

O	996	999	The
B-outcome	1000	1004	rate
I-outcome	1005	1007	of
I-outcome	1008	1017	objective
I-outcome	1018	1026	response
O	1027	1029	in
O	1030	1033	DEE
O	1034	1037	and
O	1038	1040	DE
O	1041	1046	group
O	1047	1050	was
B-iv-bin-percent	1051	1053	91
I-iv-bin-percent	1053	1054	.
I-iv-bin-percent	1054	1055	0
I-iv-bin-percent	1055	1056	%
O	1057	1060	and
B-cv-bin-percent	1061	1063	77
I-cv-bin-percent	1063	1064	.
I-cv-bin-percent	1064	1065	9
I-cv-bin-percent	1065	1066	%
O	1066	1067	,
O	1068	1080	respectively
O	1081	1082	(
O	1082	1083	p
O	1084	1085	<
O	1086	1087	0
O	1087	1088	.
O	1088	1091	001
O	1091	1092	)
O	1092	1093	.

O	1094	1096	In
O	1097	1102	spite
O	1103	1105	of
O	1106	1107	a
O	1108	1118	relatively
O	1119	1125	higher
O	1126	1138	pathological
O	1139	1147	complete
O	1148	1156	response
O	1157	1165	achieved
O	1166	1175	following
O	1176	1179	the
O	1180	1191	combination
O	1192	1199	therapy
O	1199	1200	,
O	1201	1203	no
O	1204	1215	significant
O	1216	1226	difference
O	1227	1230	was
O	1231	1236	found
O	1237	1244	between
O	1245	1248	two
O	1249	1253	arms
O	1253	1254	.

B-outcome	1255	1262	Adverse
I-outcome	1263	1269	events
O	1270	1274	were
O	1275	1281	mostly
O	1282	1284	of
O	1285	1291	Grades
O	1292	1293	1
O	1293	1294	-
O	1294	1295	2
O	1295	1296	.

O	1297	1299	No
O	1300	1311	significant
O	1312	1322	difference
O	1323	1325	in
O	1326	1333	adverse
O	1334	1339	event
O	1340	1343	and
O	1344	1347	QOL
O	1348	1351	was
O	1352	1357	found
O	1358	1365	between
O	1366	1369	the
O	1370	1373	two
O	1374	1378	arms
O	1378	1379	.

O	1380	1382	In
O	1383	1393	conclusion
O	1393	1394	,
O	1395	1398	the
O	1399	1410	combination
O	1411	1413	of
O	1414	1426	chemotherapy
O	1427	1430	and
O	1431	1433	rh
O	1433	1434	-
O	1434	1444	endostatin
O	1445	1453	achieved
O	1454	1460	better
O	1461	1469	outcomes
O	1470	1474	than
O	1475	1487	chemotherapy
O	1488	1493	alone
O	1493	1494	,
O	1495	1498	and
O	1499	1503	thus
O	1504	1507	can
O	1508	1510	be
O	1511	1521	considered
O	1522	1524	as
O	1525	1526	a
O	1527	1536	promising
O	1537	1548	therapeutic
O	1549	1557	strategy
O	1558	1561	for
O	1562	1568	breast
O	1569	1575	cancer
O	1575	1576	.
